Physician profile
Chaim Gitelis
NPI 1508086109
$9,970.88
in general payments reported to CMS, 2019-2025
28 companies · $1,532 in 2025
The $1,532 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,791 · 2020: $682 · 2021: $1,247 · 2022: $1,557 · 2023: $1,434 · 2024: $1,729 · 2025: $1,532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,643 · Education: $51.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,643.07 |
| Education | $51.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,718.76 | 2019-2025 | Farxiga, Lokelma, Brilinta |
| E.R. Squibb & Sons, L.L.C. | $1,304.20 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $905.97 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $893.87 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $713.71 | 2019-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $583.85 | 2020-2025 | |
| Novo Nordisk INC | $556.31 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $545.63 | 2019-2025 | |
| Lilly USA, LLC | $438.64 | 2022-2025 | Mounjaro, Jardiance |
| Cvrx, INC. | $375.21 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $352.29 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $251.66 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $250.01 | 2024 | Austedo Xr |
| Pharmacosmos Therapeutics INC. | $150.00 | 2024 | Monoferric |
| Edwards Lifesciences Corporation | $150.00 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $128.87 | 2025 | |
| Akebia Therapeutics INC | $125.00 | 2025 | Vafseo |
| Amneal Pharmaceuticals LLC | $109.54 | 2024 | Crexont |
| Bardy Diagnostics, INC. | $104.91 | 2021-2022 | |
| Abbott Laboratories | $73.29 | 2019-2021 | |
| Irhythm Technologies, INC. | $58.55 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Boston Scientific Corporation | $46.88 | 2024 | Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $39.78 | 2023 | |
| Vifor Pharma, INC. | $37.09 | 2019-2021 | |
| Baxter Healthcare | $16.51 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Phadia US INC. | $13.83 | 2023 | Immunocap |
| Lexicon Pharmaceuticals, INC. | $13.26 | 2024 | |
| Kiniksa Pharmaceuticals, Ltd. | $13.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chaim Gitelis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.